Kyverna Therapeutics, Inc. Common Stock (KYTX NASDAQ) stock market data APIs
$7.9613
-0.41(-5.1%)
as of February 6, 2026
Try our APIs with
free plan!
Kyverna Therapeutics, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Prev. Close
7.9613
Open
7.5477
High
8.1064
Low
7.4585
52 wk Range
1.78-13.67
Market Cap
473 M
Shares Outstanding
59 607 K
EPS
-0.85
Beta
3.479
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Kyverna Therapeutics, Inc. Common Stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Kyverna Therapeutics, Inc. Common Stock data using free add-ons & libraries
Get Kyverna Therapeutics, Inc. Common Stock Fundamental Data
Kyverna Therapeutics, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -170 456 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-13
- EPS/Forecast: -1.02
Get Kyverna Therapeutics, Inc. Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Kyverna Therapeutics, Inc. Common Stock News
New
Kyverna Therapeutics Stock Up 41% in a Month: Here's Why
Kyverna Therapeutics’ KYTX lead CAR T-cell therapy candidate, mivocabtagene autoleucel (“miv-cel”, formerly KYV-101), is being developed in a pivotal phase II study for stiff person syndrome (SP...
Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO
(RTTNews) - The biotech industry witnessed several key events this week, including major FDA approvals, acquisitions, pivotal clinical trial results and setbacks. • A series of FDA approvals were a...
KYTX Stock Rallies 23% on Upbeat Stiff Person Syndrome Study Data
Shares of Kyverna Therapeutics KYTX surged 23.2% on Monday after the company reported positive top-line data from a registrational mid-stage study of its investigational candidate, mivocabtagene autol...
5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026
After a weak first half, the drug and biotech sector has recovered in the past 2-3 months with large drugmakers like Pfizer, AstraZeneca, Eli Lilly and Novo Nordisk signing drug pricing agreements wit...
Get Kyverna Therapeutics, Inc. Common Stock fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
